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Abstract
Purpose To evaluate the therapeutic impact of [18F]fluoride
positron-emission tomography/computed tomography
([18F]fluoride PET/CT) imaging on patients with unclear
foot pain.
Methods Twenty-eight patients were prospectively included
in this study. Therapeutic management was defined by two
experienced dedicated foot surgeons before and after [18F]
fluoride PET/CT imaging. Twenty-six patients underwent
cross-sectional imaging [CT, magnetic resonance (MR)]
prior to PET/CT. A retrospective analysis of the magnetic
resonance imaging (MRI) diagnoses was performed when a
therapy change occurred after PET/CT imaging.
Results In 13/28 (46%) patients therapeutic management
was changed due to PET/CT results. Management changes
occurred in patients with the following diagnoses: os
trigonum syndrome; sinus tarsi syndrome; os tibiale
externum syndrome; osteoarthritis of several joints; non-
consolidated fragments; calcaneo-navicular coalition;
plantar fasciitis; insertional tendinopathy; suggestion of
periostitis; neoarticulations between metatarsal bones. Os
trigonum, os tibiale externum, subtalar osteoarthritis and
plantar fasciitis were only seen to be active on PET/CT
images but not on MR images.
Conclusion [18F]fluoride PET/CT has a substantial thera-
peutic impact on management in patients with unclear foot
pain.
Keywords [18F]fluoride PET/CT. Foot pain .
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Introduction
Despite advanced imaging technology, diagnostic results
after magnetic resonance (MR) and/or computed tomogra-
phy (CT) imaging in patients suffering from foot pain may
remain inconclusive. The combination of morphological
and functional imaging using fluoride positron-emission
tomography/computed tomography (PET/CT) bears the
potential to allow us to obtain a better three-dimensional
appreciation of morphology, together with metabolism,
thereby arriving at a more specific diagnosis. As a result,
it may alter and/or improve therapeutic management.
[18F]-labeled sodium fluoride (NaF) had already been used
for bone scintigraphy by Blau et al. in the 1960s. Owing to
the technical limitations of positron imaging and the
widespread availability of molybdenum-99/technetium-99m
(99Mo/99mTc) generators, 99mTc-labeled bone seeking agents
such as methylene diphosphonate (MDP) were subsequently
preferred for bone scanning. In the early 1990s [18F]fluoride
was readopted for PET scanning [1].
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[18F]fluoride is a tracer that mainly depicts blood flow
and osteoblastic activity. After intravenous (i.v.) adminis-
tration, [18F]fluoride runs through the bone capillaries and
diffuses into the bone extracellular fluid (ECF). Its plasma
clearance is more rapid, and its single-passage extraction
efficiency is higher, than that of 99mTc-MDP due to its
smaller molecular weight and its negligible protein binding.
Uptake is into hydroxyapatite crystals, which form the
mineral fluoroapatite within the bone, especially at sites of
bone remodeling. Its bone uptake is approximately two-
times greater than that of the conventional tracer 99mTc-
MDP, and its blood-to-bone clearance reaches almost
100%, with the fast bone clearance resulting in a better
target-to-background ratio. As a further advantage, [18F]
fluoride allows imaging shortly (approximately 30 min)
after i.v. administration, in contrast to the significantly
longer uptake times of 99mTc-MDP [2, 3].
Several studies have analyzed [18F]fluoride uptake in
patients with malignant and benign diseases in various
regions of the human skeleton using PET only or PET/CT.
Encouraging results have been published regarding the
detection of bone metastasis from breast cancer, lung
cancer, and thyroid and prostate cancers [4–8].
It has also been shown that planar bone scintigraphy has
a significantly lower accuracy in detecting bone metastases
than has combined bone scintigraphy and single-photon
emission computed tomography (SPECT) or [18F] PET [5].
However, while there are many studies that have
investigated the role of [18F]fluoride PET for the detection
of benign bone abnormalities, addressing the use of
quantitative PET and the evaluation of [18F]fluoride
kinetics [3, 9, 10], few studies are available that have
defined the role of static [18F]fluoride PET/(CT) for the
evaluation of non-malignant bone disorders [3, 11–14].
Recently promising results of SPECT/CT imaging in
patients with foot pain have been published [15, 16].
Owing to a worldwide shortage of molybdenum, [18F]
fluoride has become more and more attractive as an
alternative bone tracer [17, 18].
The purpose of our study was to evaluate the therapeutic
impact of [18F]fluoride PET/CT imaging on patients with
unclear foot pain. It was hypothesized that [18F]fluoride
PET/CT may be able to specify the diagnosis better and, as
a consequence, influence further treatment strategies.
Patients and methods
Patient selection
Twenty-eight patients (14 female and 14 male; mean age
47 years, age range 33–70 years) with foot pain were
prospectively enrolled in this study between November
2007 and February 2009. For these patients the specific
diagnosis for this condition had remained inconclusive after
clinical examination and/or imaging with magnetic reso-
nance imaging (MRI) and/or CT. The study was approved
by our institutional review board (IRB), and the written
informed consent of each patient was obtained.
Nine (32%) patients had a history of both trauma and
surgery; three patients (10%) had a history of surgery only,
one of them due to hemophilic arthropathy/implantation of
a talotibial joint arthrodesis, one due to debridement
because of a subtalar arthropathy, one due to osteochond-
rosis dissecans of the talus and implantation of a talotibial
joint prosthesis; nine (32%) patients had a history of
trauma without surgery, and seven (25%) had had neither
a history of surgery nor trauma. Patients had foot pain
either in the left foot (14/28; 50%), right foot (11/28;
40%), or both feet (3/28; 11%). Twenty-one patients had
undergone prior MRI; two patients had undergone CT,
and three both MRI and CT (one of the latter had had a
CT scan with intra-articular injection of contrast medium),
which all remained inconclusive regarding the origin of
the foot pain.
Radiochemistry
[18F]fluoride was produced by proton irradiation of oxygen-
18 (18O)-enriched water (RWE Nukem) in a cyclotron
(PETtrace 200, GE Health Care). After irradiation for other
[18F] tracers, the cyclotron target was rinsed with water for
injection to recover the remaining [18F]fluoride. The
recovered amount was sufficient for up to eight patients.
The [18F]fluoride in the target flush water was then purified
and formulated in 0.9% sodium chloride for injection by an
automated synthesis unit (FASTlab, GE Health Care). The
quality control for the sodium [18F]fluoride solution for
injection was in accordance with the European Pharmaco-
poeia. The radiochemical and radionuclide purity was
>98.5% and >99.9%, respectively.
Fluoride-PET/CT scanning
For this study, we used a combined PET/CT system
(Discovery STE or Discovery RX, GE Health Systems,
Milwaukee, WI, USA). This device integrates a PET
scanner with multi-slice helical CT (16 or 64 slices) and
permits the acquisition of co-registered CT and PET images
in the same session. Scanning was started approximately
30–45 min after the i.v. injection of a dose of 97–303 MBq,
mean 165 MBq of [18F]fluoride. The patients were
examined in a supine position. Immediately following the
low-dose CT image acquisition of ankles and feet [field of
view (FOV) 50 cm, tube current 80 mA, tube voltage
120 kV, slice thickness 3.75 mm, rotation time 0.5 s,
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standard reconstruction type], three-dimensional (3D) PET
emission data were acquired for 2 min per bed position.
The CT data were used for attenuation correction, and the
images were reconstructed with a standard iterative algo-
rithm (OSEM).
Additionally, a dedicated thin slice CT image [0.625 mm,
medium FOV 36 cm, 0.5 s rotation time, smartmA
(maximum 120 mA), 120 kV] was acquired, covering the
same region (standard and bone reconstruction type).
The acquired images were post-processed with dedicated
software (AW workstation, GE Health Systems) providing
multiplanar reformatted images for PET alone, CT alone
and fused PET/CT with linked cursors.
PET/CT evaluation
PET/CT images were analyzed by a dual board certified
radiologist and nuclear physician with special training in
musculoskeletal radiology and 5 years’ experience in PET/
CT reading. The reader was unaware of the results of
prior imaging examinations. Attenuation-corrected PET
images were used for analysis. The PET images were
evaluated for the presence and nature of focal lesions
with increased [18F]fluoride uptake in both feet and
lower limbs. Increased uptake of [18F]fluoride higher than
by normal appearing bone was interpreted as pathologic,
regardless whether or not pathological changes were
visible on CT scans. The thin-slice CT data were used for
exact anatomic correlation with fluoride uptake and were
analyzed for additional fluoride-PET negative important
morphological findings.
Patient treatment
Two experienced foot and ankle surgeons were asked to
define, first, the therapeutic management without the
data from the PET/CT examination, and second, the
therapeutic management with the data from the PET/
CT-examination.
All 28 patients had had foot pain for between 4 months
and 84 months (mean 27.4 months) prior to undergoing
PET/CT. As their foot pain remained unclear after the
clinical examination and the suggestion of soft-tissue
pathology was raised, the patients were primarily sent for
MRI ( 24 patients). In four patients the indication for [18F]
fluoride PET/CT was given, due to clinical suggestion of
degenerative joint disease (two of hindfoot osteoarthritis,
two of loosening of a talotibial joint prosthesis with
possible osteoarthritis of the subtalar joint).
After all 28 patients had undergone [18F]fluoride PET/
CT, the diagnoses were compared with the diagnoses
before the PET/CT, and the two surgeons decided whether
the therapeutic management had to be changed.
Retrospective analysis of MR diagnoses when a therapy
change occurred after PET/CT
A radiologist with 16 years experience in musculoskeletal
imaging retrospectively evaluated the MR images of those
13 patients for whom therapeutic management had been
changed after PET/CT. In 11/13 of the patients an MRI
scan was available with a time interval of 2 days to
6 months prior to the PET/CT imaging. First, the MR
images were evaluated with the reader unaware of the
clinical data and PET/CT findings. Second, the PET/CT
findings were retrospectively compared with those of the
MRI. Nine of the 11 MR examinations were performed
according to the in-house protocol, consisting of five MR
pulse sequences [short-tau inversion recovery (STIR)
sagittal; T1-weighted (T1-w) and T2-weighted (T2-w)
coronal; T2-w axial, and one angled T1-w axial]. Two
MR examinations had been performed in an outside
institution with a similar MR protocol, including a STIR
sequence and one with the i.v. administration of contrast
agent (Table 2).
Results
PET/CT findings
In 13/28 (46%) patients therapeutic management was
changed, based on the results of [18F]fluoride PET/CT
imaging. Of these 13 patients, nine (69%) had pain in their
left foot, 1/13 (8%) in the right foot, and 3/13 (23%) in both
feet. Four of the 13 (31%) had a history of trauma, 4/13
(31%) a history of trauma and surgery, and 5/13 (38%) had
had neither trauma nor surgery.
The main diagnoses in those patients with pain in their
left foot (9/13) were as follows: os trigonum syndrome;
sinus tarsi syndrome; osteoarthritis of the talotibial joint,
including the talofibular space and a non-consolidated
fragment of the anterior calcaneal process; non-union after
distal tibial fracture; increased activity at the lateral
calcaneal bone (possibly a periostitis); a non-consolidated
fragment of the left anterior calcaneal process; a calcaneo-
navicular coalition without significant activity; osteoarthri-
tis of the talonavicular joint and a subtalar osteoarthritis and
plantar fasciitis. One patient out of 13 who had pain in his
right foot revealed osteoarthritis of the talotibial and
subtalar joints and os tibiale externum syndrome. Three
patients out of 13 had bilateral foot pain. Of these, one
patient suffered from os trigonum syndrome on the left side
and from bilateral plantar fasciitis. The second patient with
bilateral pain showed proximal intermetatarsal neoarticula-
tions (between metatarsal bones III and IV) associated with
increased fluoride uptake. The third patient revealed
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predominant pain in the right foot and showed right-sided
osteoarthritis of the third metatarso-phalangeal joint and
osteoarthritis of the first metatarsal sesamoid bone, as well
as insertional tendinopathy of the anterior fibulotalar
ligament and increased fluoride uptake in a degenerative
lesion of the medial cuneiform on the left side (Table 1,
Figs. 1, 2, 3 and 4).
MRI findings
Of the 13 patients with changed therapeutic treatment, 11
had MR images available for retrospective analysis.
There were 15 findings from PET/CT to be compared
with those from MRI. Unaware of the PET/CT results,
the reviewer found that 6/15 (40%) of the findings from
the PET/CT were prospectively visible in the MR images,
9/15 (60%) findings were new in the PET/CT images.
After the reviewer was informed of the PET/CT findings,
two of the nine (22%) new findings in the PET/CT
images could, though less prominently, be retrospectively
confirmed in the MR images. The other seven (78%)
PET/CT findings could also not be confirmed retrospec-
tively on MRI. One of these was rather discrete on PET/
CT (Table 2).
The nine new findings by PET/CT were (time between
MRI and PET/CT in parentheses): an active os trigonum
(6 months); an active sinus tarsi (8 days); an active non-
union after a distal tibial fracture (6 months); twice a
plantar fasciitis (3 months, 22 days); subtalar osteoarthritis
(2 days); an active os tibiale externum (2 days); an active
neoarticulation between a third and forth metatarsal bone
(3 months), and osteoarthritis of a third metatarsophalan-
geal joint (5 months). The active sinus tarsi and one active
plantar fasciitis were retrospectively visible by MRI after
the reviewer became aware of the findings. The six findings
which were diagnosed by both modalities (‘blind’ evalua-
tion) were as follows: an active calcaneal periostitis in PET/
CT medially to peroneal tendons, with concomitant
tenosynovitis of the peroneal tendons on MRI (only visible
after i.v. injection of contrast agent) (5 months); an active
fragment of the left anterior calcaneal process (2 months); a
calcaneo-navicular coalition (active on MRI, not active on
PET/CT) (2 months); subtalar osteoarthritis, clearly active
only on PET/CT (3 months); one osteoarthritis of the
talotibial joint (2 days), and a osteoarthritis of a first
metatarsal sesamoid bone (5 months).
Patient treatment
Prior to PET/CT in 6/13 patients, no specific therapy had
been provided; in the other 7/13 patients infiltrations of
different joints were performed.
Therapeutic management changes induced by PET/CT in
those 13 patients were as follows:
In four patients PET/CT found increased fluoride uptake
in joints, and, subsequently, therapeutic infiltrations were
performed in a more focused way or in a different location.
Three patients without any special therapy prior to PET/CT
received infiltrations afterwards. One patient who had
received an infiltration prior to PET/CT was prescribed
orthotics. One patient without specific therapy prior to PET-
CT was treated with an infiltration on the right side in
addition to insoles, due to the PET/CT findings. In three
patients the PET/CT findings led to surgery: arthrodesis of
the subtalar joint, and resection of a non-consolidated
calcaneal fragment and of a calcaneo-navicular coalition. In
one patient the PET/CT results prevented the foot surgeons
from performing further foot-specific therapy and caused
them to refer the patient to pain specialists (Table 1).
Discussion
In our study fluoride PET/CT, using a specific foot
protocol, had a substantial impact on therapeutic decision
making by foot and ankle surgeons. PET/CT delivered
important additional information compared to prior mor-
phologic imaging by MRI and/or CT. Therapeutic manage-
ment was changed in almost one-half of all patients in our
study (46%).
Recently, Rüdisüli et al. published a study investigating
SPECT/CT in 54 patients with foot pain as their main
symptom. In their study 24 patients showed osteoarthritis,
nine patients showed osteochondrosis dissecans and 18
patients revealed miscellaneous findings such as fractures,
osteonecroses, a bone tumor, plantar fasciitis, talocalcanear
coalitions, osteomyelitis and stress reactions. Three patients
had completely normal findings. The therapeutic impact of
SPECT/CT on patient treatment was not assessed [15].
With the worldwide shortage of molybdenum [17, 18], the
increasing availability of PET scanners and the superior
image quality [2] of fluoride–PET imaging generates
increasing interest.
The dedicated foot–fluoride PET/CT protocol is highly
sensitive for the detection of metabolically active bone
lesions, especially osteoarthritis. Combination with a thin-
slice CT scan provides precise anatomic location of lesions
with increased bone turnover and can be used, for instance,
to guide therapeutic local infiltrations.
In the majority of our patients PET/CT led to therapeutic
joint infiltrations with anesthetics and corticosteroids (in
eight patients) but also to surgery (in three patients) and the
prescription of insoles/orthotics (in two patients). It could
be hypothesized that patients with fluoride-active joints in
the foot would respond better to local therapeutic injections
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than those with inactive joints, as has been shown in facet
joint osteoarthritis with conventional bone scanning [19].
Our study has several limitations. First, the time
interval between PET/CT and MRI as standard of
reference showed a wide range in this patient population
(i.e., from 2 days to 6 months in those patients whose
therapeutic management had been changed, Table 2).
Our study would have been more rigorous if the MRI had
been performed closer in time to the PET/CT and with a
standardized imaging protocol.
Fig. 2 Non-consolidated fragment of the left anterior calcaneal
process in a 36-year-old woman with pain in her left foot (patient
no. 6). a Sagittal STIR image shows the fracture of the anterior
calcaneal process with stress-like changes/edema in the adjacent bones
and joints. b Sagittal CT image shows the fracture of the anterior
calcaneal process. c Fused PET/CT-image demonstrates increased
[18F]fluoride uptake in the region of the fracture
Fig. 1 Os trigonum syndrome in a 39-year-old man with pain in his left
foot (patient no. 1). a Sagittal STIR image does not show increased
signal in the os trigonum. b Three-dimensional PET/CT fusion
demonstrates the increased activity as a red spot in the os trigonum. c
Sagittal CT image shows the os trigonum. d Fused PET/CT image
demonstrates the increased activity in the os trigonum region. e
Infiltration after PET-/CT
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Surprisingly, PET/CT in this study delivered 9/15 new
findings compared to previous MR examinations, two of
them being retrospectively confirmed but less prominent
on MRI.
Six findings could be seen both on PET/CT and MRI
(‘blinded’ evaluation). In one case no active lesion at all
was seen on PET/CT, although morphologic information
was confirmed (patient no. 7)
Interestingly, one finding on PET/CTof possible periostitis
corresponded to a soft-tissue finding on MRI after i.v.
injection of contrast agent (tenosynovitis of peroneal tendons,
patient no. 5) as an indirect sign of concomitant increased
bone activity.
The results of this study suggest the complementary
usefulness of PET/CT and MRI for patients with unclear
foot pain.
Second, this study evaluated impact on management rather
than outcome—an accepted approach in fluoro-2-deoxy-D-
glucose (FDG) PET/CT oncology literature, as outcome
studies are more difficult to perform [20, 21]. Further studies
have to confirm that [18F]fluoride PET/CT examinations
have not only an impact on therapeutic decision making but
also on patient outcome.
Third, the study has a selection bias, because patients
were only referred to PET/CT when imaging and/or clinical
diagnosis had failed to lead to an obvious diagnosis.
However, it is a standard approach to use a new imaging
technology first on patients for whom other imaging has
failed to provide a conclusive diagnosis.
In our experience [18F]fluoride PET/CT is a highly
sensitive tool showing many lesions with different uptake
intensities in both feet with and without concomitant
morphological changes. Interpretation of these multiple
uptakes might be difficult.
A thorough history and adequate clinical examination
(i.e., pain location in particular, trauma, surgery) are of
utmost importance to avoid misinterpretation of the
imaging findings. Our study population included patients
with and without a history of trauma and/or surgery. The
number of patients was limited, and the results of this
preliminary study should be confirmed in more and
specifically selected patients.
The effective dose equivalent is 0.023 mSv/MBq for
[18F]fluoride [22], which is a maximum effective dose
equivalent to 6.97 mSv in this study. The wide range of
injected activity from 97–303 MBq is explained by the fact
that we realized with increasing use of fluoride in our
institution that an administered activity of 100–150 MBq is
quite adequate to provide diagnostic images. With this ‘low
dose’ protocol, the radiation burden of fluoride PET-CT is
comparable to that of conventional SPECT/CT. Another
advantage is the short uptake time of approximately 30 min
Fig. 3 Subtalar osteoarthritis
and plantar fasciitis (left side) in
a 70-year-old woman with pain in
her left foot (patient no. 9). a
Axial T1-w image and sagittal
STIR image demonstrate only
slight irregularities of the
contour of the posterior
talocalcaneal joint. b Sagittal CT
image, with slight subchondral
sclerosis in the talocalcaneal
joint and no major plantar
changes. c Fused PET/CT image
showing increased uptake in
these regions, indicating subtalar
osteoarthritis and plantar fasciitis
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compared with 3–4 h in conventional bone scintigraphy.
One clear limitation of fluoride PET/CT compared to
conventional bone scintigraphy and SPECT is the limited
availability of [18F]fluoride and PET/(CT) scanners com-
pared to those of SPECT and bone scanning, and the higher
costs [3, 23]. The cost effectiveness of fluoride PET/CT
imaging in the diagnosis of orthopedic diseases should be
analyzed in further studies [23, 24].
Fig. 4 Osteoarthritis of the talotibial joint and subtalar joint and os
tibiale externum syndrome in a 39-year-old man with pain in his right
foot (patient no. 10). a Sagittal STIR image and axial T1-w image
show a non-active os tibiale externum. b Axial CT demonstrates the
os tibiale externum. c Fused PET/CT image shows an active os tibiale
externum. d) Sagittal STIR image and coronal T1-w image demon-
strate talotibial joint osteoarthritis and no prominent degenerative
changes of the subtalar joint. e Coronal CT shows degenerative
changes in the talotibial joint that are more than those in the subtalar
joint. f Fused PET/CT image with signs of active osteoarthritis of the
talotibial joint as well as the subtalar joint. Note that there are no
major drawbacks due to attenuation correction after osteosynthesis
994 Skeletal Radiol (2010) 39:987–997
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Conclusion
[18F]fluoride PET/CT has substantial impact on therapeutic
management, with management changes in close to half of
all patients with unclear foot pain in this prospective study.
Therefore, [18F]fluoride PET/CT appears to be a good
imaging adjunct, at least in those patients for whom the
findings of clinical examination and morphologic imaging
modalities such as MRI or CT alone remain inconclusive.
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